Jan 26, 2023 04:05PM
Oct 26, 2022 08:30AM
Oct 24, 2022 04:30PM
Oct 24, 2022 04:30PM
Oct 24, 2022 05:54AM
Oct 23, 2022 11:36PM
Oct 23, 2022 11:36PM Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
Oct 23, 2022 11:30PM
Oct 3, 2022 05:52AM
Oct 2, 2022 07:36PM
Oct 2, 2022 07:36PM
Mar 22, 2022 11:27AM
Mar 7, 2022 11:56AM
Feb 10, 2022 09:00AM Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem-Resistant Bacterial Infections
Jan 26, 2022 06:55AM
Jan 26, 2022 06:55AM
Jan 10, 2022 06:56AM
Jan 10, 2022 06:55AM
Dec 20, 2021 12:11PM
Dec 10, 2021 10:26AM
Nov 8, 2021 08:00AM Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
Nov 4, 2021 02:05PM
Oct 28, 2021 12:03PM
Oct 26, 2021 06:55AM
Oct 18, 2021 11:00AM
Oct 8, 2021 08:09PM
Oct 8, 2021 08:09PM
Sep 13, 2021 07:32AM Myovant Sciences (MYOV) Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Eff
Sep 13, 2021 07:30AM
Sep 3, 2021 08:00AM
Aug 4, 2021 09:49AM
Aug 4, 2021 09:49AM
Jul 28, 2021 06:55AM
May 26, 2021 08:00AM
May 11, 2021 06:58AM Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021
Feb 17, 2021 08:02PM
Feb 11, 2021 06:55AM
Jan 26, 2021 05:27PM
Jan 26, 2021 02:28PM
Jan 20, 2021 08:30AM
Jan 4, 2021 07:10AM
Jan 4, 2021 06:58AM Myovant Sciences (MYOV) Appoints David Marek as Chief Executive Officer
Jan 4, 2021 06:58AM
Dec 28, 2020 09:37AM
Dec 28, 2020 06:55AM
Nov 12, 2020 07:00AM
Aug 11, 2020 08:30AM
Aug 5, 2020 08:30AM
Aug 5, 2020 08:30AM Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals
Jun 22, 2020 10:14PM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All